Clinical Trials Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 26, 2024; 12(12): 2050-2055
Published online Apr 26, 2024. doi: 10.12998/wjcc.v12.i12.2050
Transient elastography with controlled attenuation parameter for the diagnosis of colorectal polyps in patients with nonalcoholic fatty liver disease
Lan Wang, Yan-Fei Li, Li-Feng Dong
Lan Wang, Yan-Fei Li, Li-Feng Dong, Department of Gastroenterology, Beijing Chuiyangliu Hospital, Beijing 100022, China
Co-first authors: Lan Wang and Yan-Fei Li.
Author contributions: Wang L, Li YF and Dong LF designed the research; Wang L performed the research; Li YF contributed new analytic tools; Wang L and Li YF analyzed the data; Wang L wrote the paper; all authors have read and approved the final manuscript.
Supported by the Special Research Project of the Capital’s Health Development, No. 2024-3-7037; and the Beijing Clinical Key Specialty Project.
Institutional review board statement: The study was approved by the Human Ethics Committee of Beijing ChuiYangLiu Hospital (No. 2024-002KY).
Informed consent statement: The requirement for informed consent from patients was waived (No. 2024-002KY).
Conflict-of-interest statement: All the authors have read and agreed with the contents of the manuscript, and there are no conflicts of interest to disclose.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at donglifeng65@sina.com.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Feng Dong, MD, Doctor, Department of Gastroenterology, Beijing Chuiyangliu Hospital, No. 2 Chuiyangliu South Street, Chaoyang District, Beijing 100022, China. donglifeng65@sina.com
Received: December 23, 2023
Peer-review started: December 23, 2023
First decision: February 24, 2024
Revised: March 7, 2024
Accepted: March 28, 2024
Article in press: March 28, 2024
Published online: April 26, 2024
Abstract
BACKGROUND

The severity of nonalcoholic fatty liver disease (NAFLD) and lipid metabolism are related to the occurrence of colorectal polyps. Liver-controlled attenuation parameters (liver-CAPs) have been established to predict the prognosis of hepatic steatosis patients.

AIM

To explore the risk factors associated with colorectal polyps in patients with NAFLD by analyzing liver-CAPs and establishing a diagnostic model.

METHODS

Patients who were diagnosed with colorectal polyps in the Department of Gastroenterology of our hospital between June 2021 and April 2022 composed the case group, and those with no important abnormalities composed the control group. The area under the receiver operating characteristic curve was used to predict the diagnostic efficiency. Differences were considered statistically significant when P < 0.05.

RESULTS

The median triglyceride (TG) and liver-CAP in the case group were significantly greater than those in the control group (mmol/L, 1.74 vs 1.05; dB/m, 282 vs 254, P < 0.05). TG and liver-CAP were found to be independent risk factors for colorectal polyps, with ORs of 2.338 (95%CI: 1.154–4.733) and 1.019 (95%CI: 1.006–1.033), respectively (P < 0.05). And there was no difference in the diagnostic efficacy between liver-CAP and TG combined with liver-CAP (TG+CAP) (P > 0.05). When the liver-CAP was greater than 291 dB/m, colorectal polyps were more likely to occur.

CONCLUSION

The levels of TG and liver-CAP in patients with colorectal polyps are significantly greater than those patients without polyps. Liver-CAP alone can be used to diagnose NAFLD with colorectal polyps.

Keywords: Colorectal polyps, Nonalcoholic fatty liver disease, Liver-controlled attenuation parameter, Liver fibroscan, Diagnostic model

Core Tip: This study was designed to explore the risk factors associated with colorectal polyps in patients with nonalcoholic fatty liver disease (NAFLD) by analyzing liver-controlled attenuation parameters (liver-CAPs) and establishing a diagnostic model. We found that the triglyceride (TG) and liver-CAPs in patients with colorectal polyps were significantly greater than those in patients without colorectal polyps. When the liver-CAP was greater than 291 dB/m, colorectal polyps were more likely to occur. Additionally, no difference was observed in the diagnostic efficacy or specificity between liver-CAP and TG+CAP. Liver-CAP alone can also be used to diagnose NAFLD patients with colorectal polyps.